[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643705":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":47,"collaborators":50,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Hospital del Mar Research Institute (IMIM)","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Adult Patients With Acute Hypoxemic Respiratory Failure Treated With HFNC",null,"Adult patients with acute hypoxemic respiratory failure receiving high-flow nasal cannula (HFNC) as part of routine clinical care. Clinical, physiological, and metabolomic data will be collected to evaluate predictors of HFNC failure and respiratory support escalation.",[13],{"name":14,"affiliation":15,"role":16},"Francisco José Parrilla-Gómez, MD, Phd","Hospital del Mar","PRINCIPAL_INVESTIGATOR",[18,22],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","+34 747424848","fparilla@hmar.cat",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":25},"Joan Ramon Masclans Enviz, MD, PhD","+34 639383309","jrmasclans@hmar.cat",[27],{"facility":15,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Barcelona","Catalonia","08003","Spain","ES",{"type":35,"coordinates":36},"Point",[37,38],2.15899,41.38879,{"lat":38,"lon":37},[41,43],{"name":23,"role":19,"phone":24,"phoneExt":10,"email":42},"jrmasclans@psmar.cat",{"name":44,"role":19,"phone":45,"phoneExt":10,"email":46},"Marta Gas Roca","+34 932483000","mgas@psmar.cat",{"type":16,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Andrea Castellvi","MD",[51,54,56,58,60,62],{"name":52,"class":53},"Instituto de Salud Carlos III","OTHER_GOV",{"name":55,"class":6},"Fundació La Marató de TV3",{"name":57,"class":6},"Hospital Universitari de Bellvitge",{"name":59,"class":6},"Hospital Universitari Joan XXIII de Tarragona.",{"name":61,"class":6},"Parc Taulí Hospital Universitari",{"name":63,"class":6},"Institute for Bioengineering of Catalonia","100643705","predicting-high-flow-nasal-cannula-failure-in-acute-hypoxemic-respiratory-failure-using-metabolomics-and-clinical-data-100643705",false,"NCT07607080","Predicting High-Flow Nasal Cannula Failure in Acute Hypoxemic Respiratory Failure Using Metabolomics and Clinical Data","Metabolomics and Clinical Data to Predict High-Flow Nasal Cannula Failure and Optimize Respiratory Support in Acute Hypoxemic Respiratory Failure","META-RESPIRE","Inclusion Criteria:\n\n* Adult patients (≥18 years old).\n* Admission to the intensive care unit (ICU) with acute hypoxemic respiratory failure (AHRF).\n* Treatment with high-flow nasal cannula (HFNC) as the initial respiratory support strategy.\n* Inclusion within the first 24 hours after HFNC initiation.\n* Provision of informed consent by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Active do-not-resuscitate (DNR) orders or limitation of therapeutic effort.\n* Refusal or inability to provide informed consent.\n* Previous invasive mechanical ventilation before study inclusion.","ALL","18 Years",{"count":75,"type":76},300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to determine whether metabolomic profiles combined with clinical data can predict high-flow nasal cannula (HFNC) failure and help optimize respiratory support in adult patients with acute hypoxemic respiratory failure (AHRF). The main questions it aims to answer are:\n\nCan metabolomic biomarkers identify patients at higher risk of HFNC failure? Does combining metabolomic and clinical data improve the prediction of respiratory support escalation and clinical outcomes?\n\nParticipants will:\n\nReceive standard HFNC treatment according to clinical practice. Undergo collection of clinical, physiological, and laboratory data. Provide blood samples for metabolomic analysis during respiratory support.",[80],"Acute Hypoxemic Respiratory Failure",[82,83,84,85,86],"Acute Hypoxemic Respiratory Failure (AHRF)","High-Flow Nasal Cannula (HFNC)","Metabolomics","Respiratory Failure Prediction","Noninvasive Respiratory Support","2026-06-04",{"date":89,"type":90},"2026-06-08","ACTUAL",{"date":87,"type":90},{"date":93,"type":76},"2029-05",{"name":5,"class":6},1]